GPT and anemia: In 21 participants evaluable for toxicity, frequent (≥ 10%) non‐dose‐limiting Grade ≥ 3 adverse events at least possibly related to protocol therapy, included anemia, decreased WBC, decreased ANC, decreased lymphocyte count, increased ALT, and hypophosphatemia (Table S1).